Butyrylcholinesterase variants and methods of use

Details Butyrylcholinesterase variants and methods of use Butyrylcholinesterase variants and methods of use

2006-07-04

2006-07-04

Celsa, Bennett (Department: 1639)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S196000, C424S094600, C530S350000

Reexamination Certificate

active

07070973

ABSTRACT:
The invention provides four butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries comprising butyrylcholinesterase variants having at least one amino acid alteration in one or more regions of butyrylcholinesterase and further having at least one butyrylcholinesterase variant exhibiting enhanced cocaine hydrolysis activity compared to butyrylcholinesterase. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.

REFERENCES:
patent: 5264563 (1993-11-01), Huse
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 6001625 (1999-12-01), Broomfield et al.
patent: 2003/0096401 (2003-05-01), Huse
patent: 2003/0153062 (2003-08-01), Watkins et al.
patent: 99/66072 (1999-12-01), None
U.S. Appl. No. 60/367,370.
OM protein—protein search using, sw model: Result 1 US to 2003/0096401.
Abremski et al., “Studies on the properties of P1 site-specific recombination: evidence for topologically unlinked products following recombination,”Cell32:1301-1311 (1983).
Bethke and Sauer, “Segmental genomic replacement by Cre-mediated recombination: genotoxic stress activation of the p53 promoter in single-copy transformants,”Nuc. Acids Res.25:2828-2834 (1997).
Blong et al., “Tetramerization domain of human butyrylcholinesterase is at the C-terminus,”Biochem. J.327:747-757 (1997).
Crameri et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,”Nature391:288-291 (1998).
Dymecki, “Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice,”Proc. Natl. Acad. Sci. U.S.A.93:6191-6196 (1996).
Fukushige and Sauer, “Genomic targeting with a positive-selectionloxintegration vector allows highly reproducible gene expression in mammalian cells,”Proc. Natl. Acad. Sci. USA89:7905-7909 (1992).
Glaser et al., “Antibody engineering by codon-based mutagenesis in a filamentous phage vector system,”J. Immunology149:3903-3913 (1992).
Gorelick, “Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy,”Drug Alcohol Depend.48:159-165 (1997).
Harel et al., “Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis,”Proc. Nat. Acad. Sci. USA89: 10827-10831 (1992).
Hoess et al., “The role of theloxPspacer region in Pl site-specific recombination,”Nucleic Acids Res.14:2287-2300 (1986).
Kunkel, “Rapid and efficient site-specific mutagenesis without phenotypic selection,”Proc. Natl. Acad. Sci. USA82:488-492 (1985).
Lockridge et al., “A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase,”Biochemistry36:786-795 (1997).
Masson et al., “Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase,”Biochemistry36:2266-2277 (1997).
Sauer and Henderson, “Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1,”Proc. Natl. Acad. Sci. USA85:5166-5170 (1988).
Schwarz et al., “Engineering of human cholinesterase explains and predicts diverse consequences of administration of various drugs and poisons,”Pharmac. Ther.67: 283-322 (1992).
Soreq et al., “Excavations into the active-site gorge of cholinesterases,”Trends Biochem. Sci.17:353-358 (1992).
Stemmer, “DNA shuffling by random fragmentation and reassembly:in vitrorecombination for molecular evolution,”Proc. Natl. Acad. Sci. USA91:10747-10751 (1994).
Sussman et al., “Atomic structure of acetylcholinesterase fromTorpedo californica: a prototypic acetylcholine-binding protein,”Science253:872-879 (1991).
Tatusova and Madden, “BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences,”FEMS Microbiol Lett.174:247-250 (1999).
Watkins et al., “Determination of the relative affinities of antibody fragments expressed inEscherichia coliby enzyme-linked immunosorbent assay,”Anal. Biochem.253: 37-45 (1997).
Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,”J. Mol. Biol.294:151-162 (1999).
Wu et al., “Stepwisein vitroaffinity maturation of Vitaxin, an αvβ3- specific humanized mAb,”Proc. Natl. Acad. Sci. USA95:6037-6042 (1998).
Xie et al., “An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient,”Molecular Pharmacology55:83-91 (1999).
Ashani, “Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs,”Drug Development Research50:298-308 (2000).
Sun et al., “Re-engineering bytyrylcholinesterase as a cocain hydrolase,” 30th Annual meeting of the Society fo Neuroscience; New Orleans, LA, USA;Society for Neuroscience Abstracts26:675.10 (2000).
GenBank Accession No. AAE40560.
GenBank Accession No. AAZ49470.
GenBank Accession No.: AAY44573.
GenBank Accession No.: AAY59235.
GenBank Accession No.: AR070208.
GenBank Accession No.: M16541.

Affiliated with

Also associated with

Rating

Butyrylcholinesterase variants and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Butyrylcholinesterase variants and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Butyrylcholinesterase variants and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3607965